Rajat Thawani, Assistant Professor at the Knight Cancer Institute at OHSU, shared a post on LinkedIn:
“New therapies are finally arriving in Small Cell Lung Cancer, but we still can’t tell early on who they’re actually working for.
So we asked a simpler question: what if a single tube of blood could tell us whether patients would benefit from Drug A vs B, before even starting the drug?
Thank you to the Kuni Foundation for funding us with a $100,000 grant to do exactly that – Blood-Based Biomarkers to Predict Response to Novel SCLC Therapies, at the OHSU Knight Cancer Institute.”
Other articles about Small Cell Lung Cancer on OncoDaily.